前列地尔联合复方丹参注射液治疗急性缺血性脑卒中的疗效观察

Effect of Alprostadil Combined with Compound Danshen Injection on Acute Ischemic Stroke

目的:探讨前列地尔联合复方丹参注射液治疗急性缺血性脑卒中(AIS)临床疗效、安全性及对再发风险的影响。方法:回顾性分析2016年4月—2020年10月接诊的132例AIS患者为研究对象,分为观察组和对照组,各66例。两组患者均接受血糖控制、血脂水平调整和抗凝治疗,对照组给予复方丹参注射液治疗,观察组在对照组基础上联合前列地尔治疗,比较两组治疗总有效率、不良反应、NIHSS评分、ADL评分及复发情况。结果:观察组治疗总有效率为95.45%,高于对照组84.85%(P<0.05);对照组不良反应总发生率为9.09%,与观察组的10.61%比较,差异无统计学意义(P>0.05);观察组ADL评分高于对照组,NIHSS评分低于对照组(P<0.05);对照组再发脑卒中风险高于观察组,差异有统计学意义(HR=2.41,95%CI:1.04~6.44,P<0.05)。结论:复方丹参注射液联合前列地尔可改善AIS患者神经功能,提高临床疗效,不增加不良反应发生率,同时可降低AIS再发风险。

Objective:To investigate the clinical efficacy,safety and impact on recurrence risk of alprostadil combined with compound Danshen injection in the treatment of acute ischemic stroke(AIS).Methods:A retrospective analysis of 132 AIS patients admitted from April 2016 to October 2020 was conducted.They were divided into observation group and control group,with 66 cases in each group.Both groups were treated with blood glucose control,blood lipid level adjustment and anticoagulant therapy.The control group was treated with compound Danshen injection,and the observation group was treated with alprostadil on the basis of the control group.The total effective rate,adverse reactions,NIHSS score,ADL score and recurrence of the two groups were compared.Results:The total effective rate of the observation group was 95.45%,which was higher than 84.85%of the control group(P<0.05).The total incidence of adverse reactions in the control group was 9.09%,which was compared with 10.61%in the observation group,the difference was not statistically significant(P>0.05).The ADL score of the observation group was higher than that of the control group,and the NIHSS score was lower than that of the control group(P<0.05).The risk of recurrent stroke in the control group was higher than that in the observation group,and the difference was statistically significant(HR=2.41,95%CI:1.04-6.44,P<0.05).Conclusion:Compound Danshen injection combined with alprostadil can improve the neurological function of AIS patients,improve the clinical efficacy,and do not increase the incidence of adverse reactions,and reduce the risk of AIS recurrence.